Showing results (151-160 of 203) with videos related to

Sort By:
Pageof 21
Gynecologic Oncology|January 18, 2017
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatinA Bergamini, C Pisano, M Di Napoli, et al.
Scandinavian Journal of Gastroenterology|March 1, 2003
Increased farnesyltransferase activity in human colorectal cancer: relationship with clinicopathological features and K-ras mutationM G Caruso, M Notarnicola, M Bifulco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2012
Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trialM Brundage, M Gropp, F Mefti, et al.
ESMO Open|September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trialE D Capoluongo, B Pellegrino, L Arenare, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2023
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trialI Ray-Coquard, A Leary, S Pignata, et al.
Gynecologic Oncology|July 25, 2020
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control studyD Lorusso, C Marchetti, C Conte, et al.
International Journal of Oncology|April 30, 2011
Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancerS Pignata, R Lauria, F Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2012
Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric studyF Zanaboni, B Grijuela, S Giudici, et al.
Critical Reviews in Oncology/Hematology|March 19, 2025
Management of early-stage ovarian cancer: Open questions and debated issuesV Salutari, E Giudice, E Rapisarda, et al.
Current Medicinal Chemistry|January 2, 2013
Deregulation of HOX B13 expression in urinary bladder cancer progressionL Marra, M Cantile, G Scognamiglio, et al.
Pageof 21